Osocimab, formerly known as BAY 1213790, represents a unique monoclonal protein currently experiencing clinical assessment for the treatment of various hematologic malignancies. This molecule specifically targets CD38, a cell receptor present on cancerous cells in illnesses like multiple myeloma